| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal ID5099: Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B |
|
Medicine details |
|
| Medicine name | concizumab |
| Formulation | subcutaneous injection |
| Reference number | 4631 |
| Indication | Prevention of bleeding episodes in haemophilia A and B |
| Company | Novo Nordisk Ltd |
| BNF chapter | Nutrition & blood |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 24/03/2023 |
| NICE guidance | ID5099: Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B |